Paving the way for real-time diagnostic guided therapy
DEDICATED TO CHANGE
Avails Medical, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and health-care associated infections. As repeatedly stated by experts around the world, antimicrobial resistance could spell the end of modern medicine.
Oren is a passionate 3rd degree black-belt Judoka. If not at Avails, Oren is refereeing international Judo tournaments as an internationally licensed IJF-B Judo referee.
Aside from her affinity to life sciences, Meike is passionate about horses and spend her free time playing polo.
Eszter obtained her PhD in Microbiology from Yale University. She was team lead of the Molecular Epidemiology group in the Mycology Unit at the Centers for Disease Control before pursuing her clinical microbiology training at UCLA and becoming board certified in medical microbiology. Eszter is well versed in the clinical microbiology workflow, knows what laboratorians need and want, what the doctors are interested in and need, and can foresee potential roadblocks in bringing in new diagnostics. Before joining Avails, Eszter was the Technical Director of the Clinical Microbiology laboratory at Santa Clara Valley Medical Center, as well as of the Kaiser Permanente Regional Laboratory in Northern California, where she gained valuable insight into how mid- and high-volume testing impacts decisions regarding what platforms, equipment and tests to bring in-house.
In her spare time, Eszter enjoys hiking, camping, going to the beach, biking and scootering with her husband and 4 year-old son.
His background includes a B.S. in Chemical Engineering and a M.S. in Material Science Engineering where he researched Beta Amyloid Protein folding for Alzheimer's research and advanced semiconductor processing. In 2019, he earned his Chemical Professional Engineering (P.E.) license. His previous professional experience was at Thermo Fisher with the Ion Torrent Next Generation Sequencer product line where he was a Staff Engineer in Sensor Design.
When not at Avails, Creighton enjoys boating, water sports -especially wakeboarding, and hiking with his family.
He obtained his PhD in Applied Physics from Yale University where his doctoral thesis work was centered around the fabrication of biological field effect transistor (BioFET) sensors applied to cancer biomarker detection. His postdoctoral fellowship work at the University of California Santa Barbara was on microfluidic biosensors. Nitin's work has been published in several high profile journals with over 1700 citations.
In his spare time, Nitin enjoys playing soccer and cooking.
BOARD OF DIRECTORS
Matthew Cooper, Ph.D., DABT, MBA, is the Chief Scientific Officer of Progenity, Inc., a provider of complex molecular and specialized diagnostic medical testing. Matthew was formerly CEO and Founder of Carmenta Bioscience, a leader in preeclampsia diagnostic development, until it was acquired by Progenity in early 2015.
Matthew’s educational background is as diverse as his professional experience with dual MBAs from Columbia Business School and the Berkeley Haas School of Business. Matthew also has a Ph.D. in Toxicology (University of Kentucky, College of Medicine) and a B.S. in Chemistry (University of Tulsa, College of Engineering). He is board certified in toxicology (Diplomat of the American Board of Toxicology) and has earned a Certificate of Entrepreneurship from the Berkeley Haas School of Business.
Dr. Berez has extensive experience in developing, gaining U.S. Government regulatory approval and marketing medical devices. He was a co-founder and CEO of Chestnut Medical Technologies, Inc., which was acquired by eV3 Inc. for more than $150 million in 2009. Before co-founding Chestnut Dr. Berez served as the VP of clinical affairs at Smart Therapeutics, Inc, which was acquired by Boston Scientific in 2003. He had previously served as the clinical director at Endovasix (acquired by Gore). He recently served as a director for Sapheon (acquired by Covidien in 2014). Dr. Berez is a graduate of the Georgetown University School of Medicine, where he received his MD degree. His postgraduate training was at UCSF/Mt. Zion in Internal Medicine, and Stanford University in Radiology and Neuroradiology, where he served as a clinical instructor in the Department of Radiology from 1997-2000.
Nancy has over 25 years of experience in the regulated industry including basic research, regulatory affairs, quality assurance, corporate compliance and clinical research. She has worked and consulted on projects including medical devices, drugs, combination products, IVDs and biologics, in various therapeutic areas. Nancy is currently the Vice President of Regulatory, Quality and Clinical Affairs at Cardiokinetix, where she has been since 2014. Prior to that, she was the Vice President of Clinical Affairs, Regulatory Affairs and Quality at NeoTract, Inc. There she successfully led the clinical IDE study and De Novo for the Urolift System. Amongst many other regulatory positions, she was also the World Wide VP of Regulatory and Quality for BD Biosciences. Nancy holds a B.S. in Cell and Molecular Biology from San Francisco State University, a J.D. from Boston University School of Law with a concentration in Health Law as well as a Masters in Public Health and Law from Harvard School of Public Health. She is a member of the California Bar. Nancy has also lectured and taught at Santa Clara Law School, Haas School of Business, Stanford Medical School and UC Santa Cruz.
Michael D. Laufer, MD has been a practicing physician and surgeon for the last three decades and a venture capitalist for the last 23 years. He is a serial entrepreneur, having conceived of and patented the technology for more than 20 companies including VNUS (IPO, acquired by Covidien, now part of Medtronic), Asthmatx (acquired by Boston Scientific), SurX (Acquired by American Medical Systems and CooperSurgical), etc. He brings expertise in early stage medical product development through FDA clearance and commercial production and growth. He is on the teaching faculty of Stanford BioDesign and has been on the surgical faculty of Harvard Medical School, the Beth Israel-Deaconess Medical Center and the Stanford Emergency/Surgical Department faculty, as well as the Medicine faculty of the University of California San Francisco.
SCIENTIFIC ADVISORY BOARD
Sir Sykes made important experimental contributions to microbiology, of which the best known are his work on B-lactamases, and the discovery of the first monocyclic B-lactam antibiotic, aztreonam. Sir Richard Sykes has over 30 years’ experience within the biotechnology and pharmaceutical industries field — serving as Chief Executive and Chairman of GlaxoWellcome from 1995–2000, then Chairman of GlaxoSmithKline until 2002. Amongst many others, Sir Richard Sykes was Rector of Imperial College London from January 2001 to June 2008.
Chief, Infectious Diseases, VA Greater Los Angeles Healthcare System
Program Director, UCLA Multicampus Program in Infectious Diseases
Professor of Clinical Medicine, David Geffen School of Medicine at UCLA
Dr. Goetz serves on the national VA Antimicrobial Stewardship Taskforce, Infectious Diseases Field Advisory Committee, Multi-Drug Resistant Organism Workgroup, and the National HIV Technical Advisory Group. He also has been an ad hoc member of the FDA Anti-Microbial Drug Advisory Committee.
Dr. Abbott is the Microbiology Director at Deaconess Health System and an adjunct faculty member of Indiana University School of Medicine in Evansville, Indiana. Dr. Abbott is a Diplomate of the American Board of Medical Microbiology. She is a member of the CLSI Subcommittee for Antimicrobial Susceptibility Testing and speaks nationally on the topic of antimicrobial susceptibility testing. She has co-authored book chapters on the topics of susceptibility testing and resistance mechanisms in the Manual of Clinical Microbiology and Tietz Textbook of Clinical Chemistry and Molecular Diagnostics.
Avails Medical is primarily a privately funded company.